Health Canada Post-Authorization Activity Table 2019-01-24, Ofev, 100 mg, 150 mg, nintedanib, capsule, oral, Boehringer…
Category: Govt of Canada
Regulatory Decision Summaries (RDSs) explain Health Canada’s decisions for certain health products seeking market authorization.
Health Canada Post-Authorization Activity Table 2019-01-15, Tafinlar, 50 mg, 75 mg, dabrafenib (as dabrafenib mesylate),…
Health Canada Summary Basis of Decision 2019-01-25. Xermelo, telotristat ethyl (as telotristat etiprate), 250 mg,…
Health Canada Post-Authorization Activity Table 2019-01-10, Zepatier, 50 mg elbasvir and 100 mg grazoprevir, tablet,…
Health Canada Summary Basis of Decision January 28, 2019. Alunbrig, brigatinib, 30 mg, 90 mg,…
Health Canada Post-Authorization Activity Table 2019-01-17, Bexsero, Recombinant Neisseria meningitidis serogroup B Neisseria Heparin Binding…
Health Canada Post-Authorization Activity Table 2018-12-20, Bosulif, 100 mg, 500 mg bosutinib, tablets, Pfizer Canada…
Health Canada Post-Authorization Activity Table 2019-01-21, Cosentyx, 150 mg/mL, secukinumab, solution, Novartis Pharmaceuticals Canada Inc.
Device Class: Type of application: Application number: Medicinal ingredient(s): Therapeutic area: Type of submission: Control…